Here is a number worth sitting with: 316 million people used illicit drugs in 2023. Not a projection. Not a worst-case estimate. The opening finding of the UNODC World Drug Report 2025, published by the United Nations Office on Drugs and Crime. That is roughly 6 per cent of every person on earth aged 15 to 64, up from 5.2 per cent a decade ago. Drug use is not holding steady. It is growing, and it is growing faster than the global population.

And the international policy machinery that was supposed to prevent this? It just had its worst year on record.

This is the first in a series examining what is actually happening to global drug policy. Not the spin, not the lobbying language, not the carefully worded ministerial statements. The real picture. Country by country, the consensus that held the line for decades is cracking. What fills the gap matters enormously, not just for policy analysts. It matters for families, for communities, for young people whose futures depend on decisions being made right now.

The Vienna Consensus Has Collapsed

For decades, the Commission on Narcotic Drugs operated by consensus. All 53 member states would find a way to agree, or nothing would move. It was imperfect, often frustratingly slow, and occasionally captured by powerful nations with a vested interest in blocking reform. But it held. It represented, however imperfectly, a shared international commitment to treating drug use as a harm worth preventing.

That ended at the 68th session of the CND in 2025.

For the first time in the commission’s history, all six resolutions put before member states were decided by a vote rather than consensus. Not one, not two. All six. The IDPC’s post-session report describes the shift plainly: the CND has become a polarised policymaking body where a new global majority can now advance resolutions that a minority of powerful states would previously have blocked indefinitely.

The most significant resolution was the establishment of an independent expert panel to review the entire international drug control machinery, championed by Colombia and backed by sixty nations. This is not a minor procedural development. It is a direct challenge to a framework largely unchanged since the 1961 Single Convention. Nations across Latin America, Africa, and parts of Europe have reached the point where they are prepared to formally question whether the architecture built around prohibition has served them well.

That challenge landed poorly with the second Trump administration. The United States, alongside Argentina, took a reactionary stance during negotiations, portraying the independent review panel as an attempt to undermine the CND’s authority. The US challenged the inclusion of harm reduction language in international agreements and distanced itself from the 2030 Agenda for Sustainable Development. For a nation that has historically positioned itself as a cornerstone of international drug control, this was a significant act of self-isolation at precisely the moment when coherent global leadership was needed most.

The Vienna Consensus did not just crack. It ended. What replaces it is still being determined, and the stakes for communities everywhere could not be higher.

What the Numbers Actually Say

While Vienna fractures, the drug use data keeps climbing. And the scale of what it shows is worth spelling out clearly.

Cannabis remains by far the most widely used drug globally, with an estimated 244 million users. But the growth in other categories is where the alarm bells ring. Opioids account for around 61 million users. Amphetamine-type stimulants sit at 30.7 million. Cocaine has climbed to 25 million users globally, up from 17 million a decade ago. Ecstasy at 21 million. Every number moving in the same direction.

Cocaine manufacture hit a record 3,708 tonnes in 2023, a 34 per cent jump from the year before. Seizures reached 2,275 tonnes over the 2019 to 2023 period, a 68 per cent rise. Western Europe has now overtaken North America as the primary destination market for cocaine, and cocaine-related deaths across European cities are climbing sharply. These are not the dynamics of a policy framework in control of the situation.

The human cost sits at nearly half a million deaths in recent years directly attributable to drug use. Twenty-eight million healthy years of life lost to disability and premature death. And just one in twelve people with drug use disorders received any form of treatment in 2023. The production side of this crisis is breaking records. The care side is barely functioning.

There are now an estimated 64 million people globally living with drug use disorders. A 13 per cent increase over the past decade. These are not statistics. They are people, mostly in families, often in communities with limited access to the support they need.

The Synthetic Opioid Surge: A Different Kind of Crisis

The drug problem of previous decades was, at least in principle, geographically constrainable. Heroin required poppy fields in Afghanistan. Cocaine required coca cultivation in the Andes. Interdiction worked when it worked because supply chains had fixed points that could be disrupted.

Synthetic opioids have no such vulnerability. Fentanyl analogues, nitazenes, new psychoactive substances engineered in real time to stay ahead of scheduling laws. A laboratory, precursor chemicals, a distribution network. Producible anywhere, shippable in quantities small enough to evade border detection, and profitable at margins that make plant-based trafficking look inefficient.

The nitazene story is particularly sobering. These synthetic opioids, some of them estimated to be up to 100 times more potent than heroin, first appeared in European death registrations only a few years ago. By 2024, nitazene-related deaths in England and Wales had quadrupled in a single year, reaching 195 fatalities. In Estonia in 2023, nitazenes were implicated in 52 per cent of all drug-related deaths. In Latvia, 66 per cent.

The UNODC is now tracking nitazene detections in Oceania and Africa. The synthetic opioid crisis, which many assumed was primarily a North American problem, is globalising. And unlike fentanyl, which at least has a relatively well-understood pharmacology, many nitazene variants are being synthesised faster than toxicologists can characterise them.

The global drug policy response to this has been piecemeal at best. Scheduling new variants takes time. Criminal networks synthesise around them faster than regulators can schedule. Harm reduction infrastructure, where it exists at all, was designed for an older drug supply. The synthetic paradigm has not just shifted the scale of the problem. It has changed its character in ways that existing frameworks were not built to handle.

Prevention Is the Response This Moment Needs

Decades of enforcement-only approaches have not suppressed global drug markets. The data is unambiguous on this. Production, distribution, and use have all continued to rise through sustained periods of law enforcement pressure. That does not mean enforcement has no role. It means enforcement alone is insufficient, and communities that have been sold it as the full answer have paid the price.

The UNODC, for all the diplomatic constraints it operates under, acknowledged this at the 2025 thematic discussions: responses must be guided by science and grounded in equity. UNODC Executive Director Ghada Waly called explicitly for investment in prevention and addressing root causes. That language matters. It reflects what decades of research into effective drug policy consistently show: communities that invest in early prevention, in family resilience, in addressing the conditions that make drug use attractive, see lower rates of uptake and lower rates of disorder.

The treatment access gap is a policy failure, not just a resource problem. One in twelve people with drug use disorders in treatment reflects a system that has deprioritised demand reduction and recovery in favour of management. Getting that ratio meaningfully higher is not idealism. It is what the evidence says works.

The remaining articles in this series examine what is happening in the United States, the United Kingdom, and Australia. Three nations whose policy choices carry real weight in shaping what comes next. The Vienna Consensus held those choices in a common frame. That frame is gone now. What replaces it will be decided, in part, by whether prevention advocates or permissive reformers fill the space first.